TABLE 1.
No. of Patients (%)a |
||||
Characteristic | Overall, N = 16,880 | PLND, N = 14,363 | No PLND, N = 2317 | P |
Age: Mean ± SD, y | 67.76 ± 10.58 | 67.55 ± 10.50 | 69.09 ± 10.98 | <0.001 |
Sex | ||||
Men | 12481 (74.8) | 10764 (74.9) | 1717 (74.1) | 0.395 |
Women | 4199 (25.2) | 3599 (25.1) | 600 (25.9) | |
Race | ||||
White | 14794 (88.7) | 12718 (88.5) | 2076 (89.6) | 0.048 |
Black | 1042 (6.2) | 891 (6.2) | 151 (6.5) | |
Other | 816 (4.9) | 729 (5.1) | 87 (3.8) | |
Unknown | 28 (0.2) | 25 (0.2) | 3 (0.1) | |
Histologic type | ||||
Transitional cell carcinoma | 15176 (91.0) | 13078 (91.1) | 2098 (90.5) | 0.007 |
Squamous cell carcinoma | 695 (4.2) | 598 (4.2) | 97 (4.2) | |
Adenocarcinoma | 258 (1.5) | 215 (1.5) | 43 (1.9) | |
Small cell carcinoma | 184 (1.1) | 169 (1.2) | 15 (0.6) | |
Neuroendocrine carcinoma | 58 (0.3) | 53 (0.4) | 5 (0.2) | |
Signet ring cell carcinoma | 99 (0.6) | 85 (0.6) | 14 (0.6) | |
Pseudosarcomatous carcinoma | 54 (0.3) | 45 (0.3) | 9 (0.4) | |
Other histology | 156 (0.9) | 120 (0.8) | 36 (1.6) | |
Grade | ||||
I | 183 (1.1) | 120 (0.8) | 63 (2.7) | <0.001 |
II | 889 (5.3) | 681 (4.7) | 208 (9.0) | |
III | 5083 (30.5) | 4300 (29.9) | 783 (33.8) | |
IV | 10525 (63.1) | 9262 (64.5) | 1263 (54.5) | |
Derived AJCC T, 6th ed | ||||
≤T1 | 2247 (13.5) | 1630 (11.3) | 617 (26.6) | <0.001 |
T2 | 6282 (37.7) | 5319 (37.0) | 963 (41.6) | |
T3 | 5204 (31.2) | 4829 (33.6) | 375 (16.2) | |
T4 | 2947 (17.7) | 2585 (18.0) | 362 (15.6) | |
Derived AJCC N, 6th ed | ||||
N0 | 12550 (75.2) | 10285 (71.6) | 2265 (97.8) | <0.001 |
N1 | 2063 (12.4) | 2031 (14.1) | 32 (1.4) | |
N2 | 1990 (11.9) | 1970 (13.7) | 20 (0.9) | |
N3 | 77 (0.5) | 77 (0.5) | 0 (0.0) |
AJCC, American Joint Committee on Cancer; SD, standard deviation of the mean; PLND, pelvic lymph node dissection. a Percentages may not add up to 100% because they were not reported completely.